Horizon Therapeutics
1 Horizon Way
Deerfield
IL
60015
United States
650 articles about Horizon Therapeutics
-
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
10/12/2022
Horizon Therapeutics plc Announces New UPLIZNA ® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022.
-
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
10/6/2022
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022.
-
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
10/2/2022
Horizon Therapeutics plc announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 in patients with low CAS.
-
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
9/29/2022
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA ® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED).
-
Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
9/22/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today expanded its commitment to education equity, science, technology, engineering, arts and math (STEAM) careers and historically Black colleges and universities (HBCUs) through its Horizon Scholars program.
-
HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics' Gout Discovery Pipeline
9/21/2022
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP).
-
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
9/21/2022
Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce the winning solution of this year’s Horizon Prize: Patient-Driven Data Platform for Rare Disease by EB Research Partnership.
-
Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
9/19/2022
Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022.
-
Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative
9/16/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has made a founding, five-year gift to establish the University of Notre Dame’s Patient Advocacy Initiative in the College of Science.
-
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology
9/14/2022
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA ® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology.
-
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
9/12/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren’s syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity.
-
Horizon Therapeutics plc Announces $500 Million Share Repurchase Program
9/9/2022
Horizon Therapeutics plc announced that its Board of Directors authorized the repurchase of up to $500 million of the Company’s ordinary shares.
-
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2022 List
9/8/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2022 list in the large company category.
-
Horizon Therapeutics plc Announces Plans to Expand its Development and Manufacturing Facility in Waterford, Ireland
8/29/2022
Horizon Therapeutics plc announced it submitted a planning application to expand its development and manufacturing facility in Waterford, Ireland to add new drug substance biologics development and manufacturing capabilities.
-
Horizon Therapeutics plc to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
8/25/2022
Horizon Therapeutics plc to Present at the Morgan Stanley 20th Annual Global Healthcare Conference.
-
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
8/15/2022
Q32 Bio and Horizon Therapeutics plc, announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.
-
Horizon Therapeutics, Eli Lilly, Gilead Sciences and more hit financial road bumps or missed the mark entirely in their Q2 earnings reports.
-
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
8/3/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced second-quarter 2022 financial results and revised its full-year 2022 net sales and adjusted EBITDA guidance.
-
Horizon Therapeutics plc Named a Best Company for Multicultural Women
7/25/2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named by Seramount (formerly Working Mother media) to its Best Companies for Multicultural Women list.
-
Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients
7/21/2022
Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients.